WATS3D Revolutionizes Barrett’s Esophagus Management with Unprecedented Early Detection Rates, Leading to Better Patient Outcomes

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SUFFERN, N.Y., Sept. 17, 2024 /PRNewswire/ — Building on recent clinical data, CDx Diagnostics today presented expert testimony underscoring the profound impact of WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis) on patient care and further demonstrating its crucial role in the management of Barrett’s esophagus (BE) and dysplasia.

With significantly enhanced detection rates, WATS3D empowers physicians to implement timely and targeted interventions.

“While the detection rate improvements are compelling, the human impact really drives home the importance of this technology,” said Dr. Matthew J. McKinley of NYU Langone.

“One in five of our patients would have likely remained unaware of their Barrett’s esophagus – a precancerous condition with a small but real risk of progressing to an esophageal cancer that has an abysmal 20% five-year survival rate. Now we can potentially monitor patients closely and take preventative measures before their disease potentially advances to a much more serious level with a dire outlook.”

With significantly enhanced detection rates, WATS3D empowers physicians to implement timely and targeted interventions, leading to better long-term patient outcomes. These findings, detailed in a recent study, translate to significant real-world impact on patient care.

The recent study Adjunctive Use of WATS-3D In Symptomatic GERD Patients Increases Detection of Barrett’s Esophagus and Dysplasia in The American Journal of Gastroenterology highlights the superior detection capabilities of WATS3D. The study found 20% more BE cases and 2x the number of dysplasia diagnoses compared to traditional methods. Also notable was that in 91% of cases with conflicting forceps results, patient care favored the WATS diagnosis, demonstrating the impact of WATS3D in clinical decision-making.

“CDx Diagnostics has processed over 400,000 WATS3D patient samples and has 23 published studies supporting its efficacy, making it a game-changer in esophageal precancer detection. With WATS3D integrated into routine practice, healthcare providers can offer superior care and peace of mind to their patients,” says Tom Bartel, Executive Vice President of Sales at CDx Diagnostics.

For more information about WATS3D and its benefits, please visit www.cdxdiagnostics.com or email us at WATS3D@cdxdiagnostics.com.

About CDx Diagnostics

CDx Diagnostics is driven by its mission to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. The company’s proprietary diagnostic platform combines advanced computer imaging, artificial intelligence, molecular biology, and 3D cytopathology to detect precancerous changes earlier and with greater precision than conventional methods.  By addressing a critical gap in the current diagnostic standard of care, CDx’s pioneering solutions have enabled the early detection of thousands of cancers and precancerous conditions, unlocking opportunities for timely and effective treatment.

View original content:https://www.prnewswire.com/news-releases/wats3d-revolutionizes-barretts-esophagus-management-with-unprecedented-early-detection-rates-leading-to-better-patient-outcomes-302250442.html

SOURCE CDx Diagnostics

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

6 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

6 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

9 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

9 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

9 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

9 hours ago